Diabetes or obesity
Conditions
Interventions
Experimental group(GLP-1RA+ compound glutamine):Compound Glutamine
Control group(GLP-1RA + placebo):Placebo
Sponsors
The Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 to 70 years (including 18 and 65 years) with diabetes (ADA Medical Standards 2025) or obesity (Guideline for the Management of obesity (2024 version)) who use GLP-1RA for weight loss or blood glucose control and experience gastrointestinal adverse effects (such as nausea, vomiting, abdominal distension, diarrhea) during the use of GLP-1RA. 2. No prior history of digestive system diseases 3.Well-controlled blood pressure (below 140/90 mmHg) with stable levels for over 2 weeks 4. Gender-neutral participants with clear understanding, willingness to join the study, ability to take medication regularly, and readiness to actively cooperate with treatment may be enrolled as trial subjects.
Exclusion criteria
Exclusion criteria: 1.merge severe heart diseases, respiratory diseases, digestive system diseases, personal or family history of thyroid tumors, type 2 multiple endocrine neoplasia syndrome, and other diseases 2.pregnant women 3.individuals prone to ketoacidosis 4.those with prior drug allergies 5. patients with a history of recurrent pancreatitis 6. individuals with diabetic retinopathy 7. patients with life-threatening conditions or mental health disorders such as depression or anxiety 8.patients concurrently enrolled in other clinical drug trials. 9. Patients who are not suitable for this study are considered by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastrointestinal adverse reactions;Fasting blood glucose;Glycated hemoglobin;Blood glucose two hours after a meal;Fasting insulin;Fasting C-peptide;HOMA-IR;HOMA-ß index;Total cholesterol;Triglyceride;High-density lipoprotein;Low-density lipoprotein;Malondialdehyde;TNF-a;High-sensitivity C-reactive protein, hs-CRP;Lipopolysaccharide, LPS; | — |
Countries
China
Contacts
Public ContactChenlin Gao
The Affiliated Hospital of Southwest Medical University
Outcome results
None listed